PHAT — Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenues: $58.3 million, up 104% year-over-year from $28.5 million in Q1 2025.
• Cash Operating Expenses: $56.2 million, reflecting disciplined expense management; down 43% year-over-year.
• Net Cash Usage: Approximately $15 million for Q1 operations.
• Gross Margin: Approximately 80%, in line with guidance.
• New Prescriptions: 1.35 million VOQUEZNA prescriptions filled through April 17, with a significant increase in covered prescriptions (up 91% year-over-year).
• New-to-Brand Prescription Share: Approximately 45% among top 300 gastroenterology writers.

2. Strategic Updates and Business Highlights

• Expanded sales team with nearly 50 new representatives, totaling over 290 reps focused on gastroenterology.
• Focus on increasing market share among gastroenterologists, targeting 20%-30% for the first $1 billion in annual revenue from GI prescriptions.
• Positive trends in prescribing behaviors, particularly in new-to-brand conversions, indicating early success of the gastroenterology-focused strategy.
• VOQUEZNA is positioned as a leading therapy for erosive esophagitis, with strong clinical data supporting its efficacy.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Maintained at $320 million to $345 million.
• Gross to Net Discount: Expected to remain within 55% to 59%.
• Operating Expenses: Anticipated between $235 million to $255 million for the year.
• Profitability Outlook: Expected to achieve operating profitability (excluding stock-based compensation) by Q3 2026, with positive cash flow anticipated in 2027.

4. Bad News, Challenges, or Points of Concern

• Market Access Seasonality: Q1 revenues were slightly below internal expectations due to seasonal factors and deployment timing of the new sales force.
• Competition: Potential entry of a second P-CAB product (Tegoprazan) in 2027 could impact market dynamics and pricing pressures.
• Cash Pay Dynamics: An increase in cash pay prescriptions was noted in Q1, which may normalize in subsequent quarters.

5. Notable Q&A Insights

• Competition and Market Dynamics: CEO Steve Basta expressed confidence in VOQUEZNA's strong market position despite the potential entry of Tegoprazan, citing high healing rates and positive patient feedback as key advantages.
• Prescription Growth Drivers: The growth in prescriptions is driven by both erosive esophagitis and non-erosive reflux disease (NERD) patients, with a natural progression in physician adoption from severe to less severe cases.
• M&A Considerations: Phathom is exploring potential acquisitions of complementary GI assets but is not in a rush, focusing instead on maximizing the current sales force's effectiveness.
• Patient Feedback Impact: Positive patient experiences are driving physician recommendations and future growth potential, particularly as patients cycle back to primary care.

Overall, Phathom Pharmaceuticals reported strong growth in Q1 2026, driven by strategic focus on gastroenterology and positive market reception of VOQUEZNA, while also navigating competitive pressures and market dynamics.